ALA

AROVELLA FPO [ALA]
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Healthcare · ASX Small Cap
$0.0640 -1.5%

Updated 23 Jul 2026 · Signals refresh every scan

Get alerts when ALA triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track ALA — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Strong cash runway (11 quarters)
  • Near 52-week low (6% of range)
  • Small-cap ($20-100M)
  • CANSLIM I: Institutional ownership (12%)
  • Sentiment is mixed — no strong consensus either way
  • Altman Z-Score grey zone (1.85, low-confidence approx)
  • Beneish M-Score 4.12 > -1.78: likely earnings manipulation
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 7d (+3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Revenue declining (-7%)
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-247%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 28% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.05%/day)
Ask Scout AI about ALA
"What's driving ALA today?" "How does ALA compare to peers?" "Key risks for ALA?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Notice under Section 708A
NONE Notification of cessation of securities - ALA
NONE Application for quotation of securities - ALA

Recent ASX Announcements

2026-06-29 Notice under Section 708A
2026-06-29 Notification of cessation of securities - ALA
2026-06-29 Application for quotation of securities - ALA
2026-06-24 First-In-Human Trial
2026-06-09 Change of Director's Interest Notice

Key Metrics

$79.8M
Market Cap
675K
Avg Volume
0.4x
Vol Ratio
$0.06 — $0.12
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-52.0%
ROE
-246.9%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 75%
LLeader vs LaggardlaggardRS: -12
IInstitutional SponsorshippassInst: 12%
MMarket DirectionneutralNeutral

Sector: Healthcare

102 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
PIQ +23.3%SLD -18.1%ADR -17.9%IDT -17.1%VBS -14.3%
Compare:ALA vs PIQALA vs SLDALA vs ADR
Scout Pro — Deeper Analysis for ALA
Try Pro free for 30 days
Share this analysis

Track ALA and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required